Online citations, reference lists, and bibliographies.
← Back to Search

Management Of Platinum-resistant Ovarian Cancer With The Combination Of Pemetrexed And Gemcitabine

J. G. Blesa, V. A. Candel, M. P. Pulla, E. González, S. Algarra
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Introduction Platinum resistant ovarian cancer is a current challenge in Oncology. Current approved therapies offer no more of a 20% of response. New therapeutic options are urgently needed.
This paper references
The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.
R. Zhao (2000)
10.1093/JNCI/86.20.1530
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
B. Lund (1994)
10.1200/JCO.2004.05.195
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
M. Markman (2004)
10.1200/JCO.2000.18.8.1748
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
A. Adjei (2000)
10.1007/s10637-006-9020-9
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
M. Galsky (2006)
10.1200/JCO.1997.15.3.987
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
F. Muggia (1997)
10.1016/J.YGYNO.2007.01.038
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
E. Han (2007)
10.1200/JCO.2007.12.0782
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
S. Cannistra (2007)
10.1159/000140360
Schedule-Dependent Synergistic Effect of Pemetrexed Combined with Gemcitabine against Malignant Pleural Mesothelioma and Non-Small Cell Lung Cancer Cell Lines
S. Nagai (2008)
10.1097/00000421-199502000-00004
A Phase II Trial of 5‐Fluorouracil and High‐Dose Leucovorin in Recurrent Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
K. Y. Look (1995)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.3322/canjclin.57.1.43
Cancer Statistics, 2007
A. Jemal (2007)
10.1016/S0093-7754(02)70050-X
Pemetrexed in bladder, head and neck, and cervical cancers.
L. Paz-Ares (2002)
10.1159/000106069
A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors
A. Kalykaki (2006)
Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
J. L. Tonkinson (1999)
10.1038/sj.bjc.6604442
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
10.1200/JCO.2001.19.19.3967
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer.
D. Clarke-Pearson (2001)
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
C. Shih (1997)
Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study.
R. Slayton (1979)
10.1016/J.YGYNO.2007.07.017
Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
J. Chura (2007)
10.1002/cncr.21969
Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma
J. Wright (2006)
10.1200/JCO.1998.16.2.405
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
P. Rose (1998)
10.1158/1078-0432.CCR-03-0520
Synergistic Cytotoxicity and Pharmacogenetics of Gemcitabine and Pemetrexed Combination in Pancreatic Cancer Cell Lines
E. Giovannetti (2004)
10.1053/j.seminoncol.2008.02.008
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
W. Dean-Colomb (2008)
10.1200/JCO.2007.11.5345
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
R. Burger (2007)
10.1200/JCO.1999.17.8.2553
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
H. Hochster (1999)
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
B. Teicher (1999)
10.1158/1078-0432.CCR-03-0787
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
G. Rustin (2004)
10.1002/1097-0142(20010801)92:3<595::AID-CNCR1359>3.0.CO;2-D
Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma
F. Shepherd (2001)
10.3747/CO.2007.148
Optimal chemotherapy treatment for women with recurrent ovarian cancer
M. Fung-Kee-Fung (2007)
Phase II studies of pemetrexed in metastatic breast and gynecologic cancers.
I. Smith (2004)
10.1038/sj.bjc.6603242
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
V. Mey (2006)
10.1200/JCO.2001.19.14.3312
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A. Gordon (2001)
10.1006/GYNO.1996.0181
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
M. Markman (1996)
10.1023/A:1008469212268
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
M. Friedlander (1998)
10.1006/GYNO.2000.6089
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
P. Sørensen (2001)
10.1080/07357900500449595
Ifosfamide/Mesna as Salvage Therapy in Platinum Pretreated Ovarian Cancer Patients—Long-Term Results of a Phase II Study
M. Baur (2006)
10.1006/GYNO.1998.5065
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
M. Markman (1998)
10.1200/JCO.2006.24.18_SUPPL.5083
A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): Dosing results and evidence of activity.
M. Hensley (2006)
10.1158/1078-0432.CCR-06-2878
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
J. Smyth (2007)
10.1016/J.IJROBP.2005.12.004
Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases.
F. Lordick (2006)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar